HARP Overzicht aandelen
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Harpoon Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$23.01 |
| 52 Week Hoogtepunt | US$23.21 |
| 52 Week Laag | US$3.11 |
| Bèta | 2.1 |
| 11 maand verandering | 2.49% |
| 3 maanden verandering | 162.97% |
| 1 Jaar Verandering | 243.43% |
| 33 jaar verandering | -88.71% |
| 5 jaar verandering | -81.26% |
| Verandering sinds IPO | -82.96% |
Recent nieuws en updates
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Rendement voor aandeelhouders
| HARP | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.2% | 2.4% | 2.2% |
| 1Y | 243.4% | 16.2% | 31.7% |
Rendement versus industrie: HARP overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 15.2 % opleverde.
Rendement versus markt: HARP overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.
Prijsvolatiliteit
| HARP volatility | |
|---|---|
| HARP Average Weekly Movement | 32.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van HARP is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van HARP is het afgelopen jaar gestegen van 21% naar 33%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc. Samenvatting
| HARP fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$492.35m |
| Inkomsten(TTM) | -US$30.50m |
| Inkomsten(TTM) | US$37.34m |
13.2x
P/S-verhouding-16.1x
Koers/WinstverhoudingIs HARP overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HARP resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$37.34m |
| Kosten van inkomsten | US$58.63m |
| Brutowinst | -US$21.29m |
| Overige uitgaven | US$9.21m |
| Inkomsten | -US$30.50m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.43 |
| Brutomarge | -57.02% |
| Nettowinstmarge | -81.67% |
| Schuld/Eigen Vermogen Verhouding | 194.4% |
Hoe presteerde HARP op de lange termijn?
Bekijk historische prestaties en vergelijking